$29.10
-0.68-2.28%
At close: -
$29.10
0.000.00%
After Hours: Mar 28, 4:00 PM EDT
Comments
Loading...
Janux Therapeutics Insider Trading Activity | NASDAQ:JANX | Benzinga
Track the latest Janux Therapeutics insider trading activity. Stay informed on recent buys, sells, and market impact for Janux Therapeutics stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Janux Therapeutics Inc Insiders Doing?
At Janux Therapeutics Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have report no sales in the last 30 days, meanwhile, insiders have reported buying a total of 824.04K shares for a total value of $25.34M.
Notable Recent Insider Buys and Sales
- On March 7, 2025, RA CAPITAL MANAGEMENT LP, RA Capital Healthcare Fund LP, RA Capital Nexus Fund II LP, Peter Kolchinsky, Rajeev Shah, the company's DIRECTOR purchased 824.04K shares for $30.75 each.
- On January 8, 2025, Alan David Campbell, the company's PRESIDENT AND CEO sold 5K shares for $60 each.
Ownership Statistics for Janux Therapeutics Inc
Shares Outstanding
59.105M
Insider Shares Owned
1.136M
Insider Percentage Owned
1.92%
Institutional Shares Held
24.859M
Institutional Percentage Held
42.1%
| Mar 07, 2025 | RA CAPITAL MANAGEMENT LPRA Capital Healthcare Fund LPRA Capital Nexus Fund II LPPeter KolchinskyRajeev Shah | DIRECTOR | 824.04K | $30.75 | $25.34M | BUY | 7.95% | 11.19M | Mar 05 - Mar 07 | View |
| Mar 05, 2025 | Hollman Andrew Meyer | CHIEF BUSINESS OFFICER | 0.00 | $18.18 | -$93.14K | SELL-OPTIONS | 0.00% | 82.14K | Mar 03 | View |
| Feb 05, 2025 | Hollman Andrew Meyer | CHIEF BUSINESS OFFICER | 0.00 | $23.25 | -$126.96K | SELL-OPTIONS | 0.00% | 82.14K | Feb 03 | View |
| Jan 08, 2025 | Alan David Campbell | PRESIDENT AND CEO | -5.00K | $60.00 | -$300.00K | SELL | -1.68% | 293.05K | Jan 07 | View |
| Jan 03, 2025 | Hollman Andrew Meyer | CHIEF BUSINESS OFFICER | 4.67K | $54.88 | -$731.79K | GRANT | 6.02% | 82.14K | Jan 02 | View |
| Dec 27, 2024 | Alan David Campbell | PRESIDENT AND CEO | -25.00K | $56.19 | -$1.40M | SELL | -10.33% | 217.05K | Dec 24 | View |
| Dec 03, 2024 | Alan David Campbell | PRESIDENT AND CEO | -15.00K | $67.00 | -$1.00M | SELL | -5.84% | 242.05K | Dec 03 | View |
| Nov 27, 2024 | Alan David Campbell | PRESIDENT AND CEO | -25.00K | $51.60 | -$1.29M | SELL | -8.86% | 257.05K | Nov 25 | View |
| Oct 30, 2024 | Alan David Campbell | PRESIDENT AND CEO | -25.00K | $53.54 | -$1.34M | SELL | -8.14% | 282.05K | Oct 28 | View |
| Oct 24, 2024 | Jay Lichter | — | 0.00 | $31.98 | -$112.13K | SELL-OPTIONS | 0.00% | 3.03M | Sep 13 | View |
| Oct 22, 2024 | RA CAPITAL MANAGEMENT LPRA Capital Healthcare Fund LPRA Capital Nexus Fund II LPPeter KolchinskyRajeev Shah | DIRECTOR | 1.20M | $44.75 | $53.70M | BUY | 13.09% | 10.37M | Oct 18 | View |
| Oct 18, 2024 | Avalon Ventures XI LPAvalon BioVentures I LPAvalon BioVentures SPV I LPJay Lichter | 10% OWNER | -1.66M | $32.19 | -$77.25M | SELL | -43.98% | 2.12M | Oct 16 - Oct 18 | View |
| Sep 30, 2024 | Avalon Ventures XI LPAvalon BioVentures I LPAvalon BioVentures SPV I LPJay Lichter | 10% OWNER | -305.11K | $32.51 | -$14.40M | SELL | -97.79% | 6.89K | Sep 26 - Sep 30 | View |
| Sep 27, 2024 | Hollman Andrew Meyer | CHIEF BUSINESS OFFICER | 0.00 | $25.08 | -$2.09M | SELL-OPTIONS | 0.00% | 67.59K | Sep 27 | View |
| Sep 27, 2024 | Thomas DiRaimondo | CHIEF SCIENTIFIC OFFICER | -5.00K | $46.34 | -$231.72K | SELL | -4.86% | 97.94K | Sep 27 | View |
| Sep 27, 2024 | Alan David Campbell | PRESIDENT AND CEO | -25.00K | $46.31 | -$1.16M | SELL | -7.53% | 307.05K | Sep 27 | View |
| Sep 12, 2024 | Avalon Ventures XI LPAvalon BioVentures I LPAvalon BioVentures SPV I LPJay Lichter | 10% OWNER | -451.09K | $46.89 | -$21.15M | SELL | -12.96% | 3.03M | Sep 10 - Sep 12 | View |
| Sep 10, 2024 | Avalon Ventures XI LPAvalon BioVentures I LPAvalon BioVentures SPV I LPJay Lichter | 10% OWNER | -240.08K | $30.01 | -$10.13M | SELL | -97.17% | 7.00K | Sep 06 - Sep 09 | View |
| Jun 05, 2024 | Jay Lichter | — | -1.50M | $54.75 | -$82.13M | SELL | -30.96% | 3.34M | Jun 03 | View |
| Jun 05, 2024 | Tighe Reardon | ACTING CHIEF FINANCIAL OFFICER | -822.72K | $54.75 | -$45.04M | SELL | -18.97% | 3.52M | Jun 03 | View |
| Jun 05, 2024 | Avalon Ventures XI LPAvalon BioVentures I LPAvalon BioVentures SPV I LP | 10% OWNER | -1.50M | $54.75 | -$82.13M | SELL | -30.99% | 3.34M | Jun 03 | View |
| Nov 15, 2023 | Tighe Reardon | ACTING CHIEF FINANCIAL OFFICER | 849.85K | $5.87 | $4.99M | BUY | 18.97% | 5.33M | Nov 13 | View |
| Nov 15, 2023 | Jay Lichter | DIRECTOR | 849.85K | $5.87 | $4.99M | BUY | 18.97% | 5.33M | Nov 13 | View |
| Nov 13, 2023 | Avalon Ventures XI LPAvalon BioVentures SPV I LPAvalon BioVentures I LP | 10% OWNER | 849.85K | $5.87 | $4.99M | BUY | 18.97% | 5.33M | Nov 13 | View |
| Jul 21, 2023 | RA CAPITAL MANAGEMENT LPRA Capital Healthcare Fund LPRA Capital Nexus Fund II LPPeter KolchinskyRajeev Shah | DIRECTOR | 495.01K | $12.46 | $6.17M | BUY | 5.71% | 9.17M | Jul 19 | View |
| Dec 30, 2021 | ORBIMED ADVISORS LLCOrbiMed Capital GP VIII LLCOrbiMed Genesis GP LLC | DIRECTOR | -40.40K | $20.30 | -$820.12K | SELL | -14.88% | 231.10K | Dec 29 | View |
| Dec 30, 2021 | Peter Thompson | DIRECTOR | -40.40K | $20.30 | -$820.12K | SELL | -14.88% | 231.10K | Dec 29 | View |
| Dec 23, 2021 | ORBIMED ADVISORS LLCOrbiMed Capital GP VIII LLCOrbiMed Genesis GP LLC | DIRECTOR | -119.40K | $19.00 | -$2.27M | SELL | -33.71% | 234.80K | Dec 21 | View |
| Dec 23, 2021 | Peter Thompson | DIRECTOR | -119.40K | $19.00 | -$2.27M | SELL | -33.71% | 234.80K | Dec 21 | View |
| Dec 17, 2021 | Peter Thompson | DIRECTOR | -393.30K | $19.07 | -$7.50M | SELL | -61.53% | 245.90K | Dec 16 | View |
| Dec 17, 2021 | ORBIMED ADVISORS LLCOrbiMed Capital GP VII LLCOrbiMed Genesis GP LLC | DIRECTOR | -393.30K | $19.07 | -$7.50M | SELL | -61.53% | 245.90K | Dec 16 | View |
| Jun 16, 2021 | Bregua Corp | 10% OWNER | 3.75M | $17.00 | $999.99K | BUY | ∞ | 3.75M | Jun 15 | View |
| Jun 16, 2021 | Peter Thompson | DIRECTOR | 3.04M | $17.00 | $12.00M | BUY | ∞ | 282.40K | Jun 15 | View |
| Jun 16, 2021 | ORBIMED ADVISORS LLCOrbiMed Capital GP VIII LLCOrbiMed Genesis GP LLC | DIRECTOR | 3.04M | $17.00 | $12.00M | BUY | ∞ | 282.40K | Jun 15 | View |
| Jun 16, 2021 | Tighe Reardon | ACTING CHIEF FINANCIAL OFFICER | 4.48M | $17.00 | $10.70M | BUY | 2590.27% | 4.65M | Jun 15 | View |
| Jun 16, 2021 | Jay Lichter | DIRECTOR | 8.67M | $17.00 | $10.70M | BUY | ∞ | 4.48M | Jun 15 | View |
| Jun 16, 2021 | Avalon Ventures XI LPAvalon BioVentures SPV I LP | 10% OWNER | 8.67M | $17.00 | $10.70M | BUY | ∞ | 4.48M | Jun 15 | View |
| Jun 16, 2021 | RA CAPITAL MANAGEMENT LPRA Capital Healthcare Fund LPPeter KolchinskyRajeev Shah | DIRECTOR | 8.67M | $17.00 | $50.00M | BUY | ∞ | 1.05M | Jun 15 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.